TARSUS PHARMACEUTICALS, INC. Capital Expenditures
TARSUS PHARMACEUTICALS, INC. (TARS) reported Capital Expenditures of $9.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $4.07M, a 306.49% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $5.82M, a 886.10% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $6.36M, a 8730.56% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $1.91M, a 577.30% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $9.86M, a 529.16% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $1.57M, a 4.33% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $1.50M, a 196.84% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $506.00K, a 13.65% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.89M 10-Q · filed 2026-08-06 | $16.25M derived: sum of 3 quarters · filed 2026-08-06 | $18.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.82M 10-Q · filed 2026-05-06 | $12.18M derived: sum of 2 quarters · filed 2026-05-06 | $14.09M derived: sum of 3 quarters · filed 2026-05-06 | $15.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.27M derived: sum of 2 quarters · filed 2026-02-23 | $9.27M derived: sum of 3 quarters · filed 2026-08-06 | $9.86M 10-K · filed 2026-02-23 |
| 2025-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.91M derived: sum of 2 quarters · filed 2026-08-06 | $3.50M 10-Q · filed 2025-11-04 | $3.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.59M 10-Q · filed 2026-08-06 | $1.66M derived: sum of 3 quarters · filed 2026-08-06 | $1.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $590.00K 10-Q · filed 2026-05-06 | $662.00K derived: sum of 2 quarters · filed 2026-05-06 | $944.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.98M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $354.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.39M derived: sum of 3 quarters · filed 2026-02-23 | $1.57M 10-K · filed 2026-02-23 |
| 2024-09-30 | $282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.32M derived: sum of 2 quarters · filed 2025-11-04 | $1.50M 10-Q · filed 2025-11-04 | $1.50M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.21M 10-Q · filed 2025-08-06 | $1.21M derived: sum of 3 quarters · filed 2026-02-23 | $1.59M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $174.00K 10-Q · filed 2025-05-01 | $174.00K derived: sum of 2 quarters · filed 2026-02-23 | $549.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.34M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $375.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.16M derived: sum of 3 quarters · filed 2026-02-23 | $1.50M 10-K · filed 2026-02-23 |
| 2023-09-30 | $375.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.16M derived: sum of 2 quarters · filed 2024-11-13 | $1.50M 10-Q · filed 2024-11-13 | $1.63M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $787.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.13M 10-Q · filed 2024-08-08 | $1.25M derived: sum of 3 quarters · filed 2025-02-25 | $1.35M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $340.00K 10-Q · filed 2024-05-08 | $467.00K derived: sum of 2 quarters · filed 2025-02-25 | $563.00K derived: sum of 3 quarters · filed 2025-02-25 | $685.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $223.00K derived: sum of 2 quarters · filed 2025-02-25 | $345.00K derived: sum of 3 quarters · filed 2025-02-25 | $506.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $218.00K derived: sum of 2 quarters · filed 2023-11-09 | $379.00K 10-Q · filed 2023-11-09 | $653.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $283.00K 10-Q · filed 2023-08-10 | $557.00K derived: sum of 3 quarters · filed 2023-08-10 | $678.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $161.00K 10-Q · filed 2023-05-09 | $435.00K derived: sum of 2 quarters · filed 2023-05-09 | $556.00K derived: sum of 3 quarters · filed 2023-05-09 | $572.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $395.00K derived: sum of 2 quarters · filed 2023-03-17 | $411.00K derived: sum of 3 quarters · filed 2023-03-17 | $586.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $137.00K derived: sum of 2 quarters · filed 2022-11-09 | $312.00K 10-Q · filed 2022-11-09 | $262.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $191.00K 10-Q · filed 2022-08-11 | $141.00K derived: sum of 3 quarters · filed 2022-08-11 | $276.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $175.00K 10-Q · filed 2022-05-11 | $125.00K derived: sum of 2 quarters · filed 2022-05-11 | $260.00K derived: sum of 3 quarters · filed 2022-05-11 | $595.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $85.00K derived: sum of 2 quarters · filed 2022-03-14 | $420.00K derived: sum of 3 quarters · filed 2022-03-14 | $456.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $470.00K derived: sum of 2 quarters · filed 2021-11-10 | $506.00K 10-Q · filed 2021-11-10 | $530.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $335.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $371.00K 10-Q · filed 2021-08-05 | $395.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $36.00K 10-Q · filed 2021-05-11 | $60.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $175.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $151.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |